Osteoclast


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

osteoclast

[′äs·tē·ə‚klast]
(histology)
A large multinuclear cell associated with bone resorption.
(medicine)
A large surgical apparatus through which leverage can be exerted to effect osteoclasis.

Osteoclast

 

a cell that is involved in the destruction and resorption of bone tissue in vertebrate animals and man. An osteoclast contains from three to several dozen nuclei and a great many lysosomes, whose hydrolytic enzymes upon release from the osteoclasts resorb the mineral matrix of bone and calcified cartilage.

References in periodicals archive ?
NFATc1 translocates to the nucleus and induces the expression of multiple osteoclast markers, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K, and cellular tyrosine protein kinase-Src (c-Src) (Boyle et al.
Intriguingly, humans with cathepsin K mutations have skeletal hypermineralization and increased fracture risk, with bone biopsies demonstrating normal or increased osteoclast numbers.
Key Words: Diabetes Mellitus, Orthodontic Tooth Movement, Osteoclast, Bone Remodeling.
Osteoclast malfunction resulting in primary sclerosing conditions of bone must be differentiated from several conditions wherein bone sclerosis results as a secondary phenomenon.
Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
Osteoblasts regulate osteoclast activity through the secretion of RANKL.
24) With the background that RANKL/RANK signaling is essential for osteoclast formation, major studies have focused on the area to determine the full extent of the involvement of RANKL in osteoclast biology and common bone diseases.
In 2007, a novel study was conducted by Simpson et al, in which they used mature osteoclasts to demineralize calcified elastin in vitro and in vivo [2].
Osteoclast formation and tartrate-resistant acid phosphatase (TRAP) staining
5) Odanacatib appears to mainly suppress bone resorption with only a transient effect on bone formation and does not seem to impact osteoclast survival.
By targeting the receptor activator of nuclear factor-kappaB ligand (RANKL), which is the primary mediator of osteoclast formation, denosumab blocks the production of the bone-destroying osteoclasts and by so doing improves the density, volume, and strength of both cortical and trabecular bone, according to the authors (N.